FYB206 Becomes First Publicly Announced Keytruda Biosimilar Under FDA Review
Formycon and Zydus said the FDA accepted FYB206 for review, making it the first publicly announced Keytruda biosimilar in the process.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Newsmetry API reports that Formycon AG and Zydus announced the FDA has accepted FYB206 for review.
The companies said FYB206 is the first publicly announced Keytruda biosimilar to enter the US regulator’s review process.
why it matters
FDA acceptance moves the product into a formal regulatory process and may matter for how investors assess Formycon and Zydus in this segment.
instruments
sources
- Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA — Newsmetry API, 13 October 2026 at 04:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗